NCT05451290View on ClinicalTrials.gov

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

May 31, 2025

Study Completion Date

September 1, 2025

Conditions

Advanced Biliary Tract Carcinoma

Interventions

DRUG

Camrelizumab, apatinib, gemcitabine, oxaliplatin, tegafur

Perioperative treatment: camrelizumab plus apatinib in combination with GEMOX 2-4 cycles (neoadjuvant); camrelizumab plus tegafur up to 1 year (adjuvant).

Trial Locations (1)

310003

RECRUITING

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors

lead

First Affiliated Hospital of Zhejiang University

OTHER